2020 ASCO Virtual Direct™ Highlights

 

GI
08:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ctDNA: What Are the Potential Clinical Implications for Treatment Decision and Disease Monitoring? Can We Use It as an Additive Information for Prognostic Risk Assessment?

FEATURING Martin Dietrich
  • 174 views
  • November 11, 2020
  • 1
11:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on ctDNA in CRC: Can It Help Detect MRD, Response to Adjuvant Therapy and Identify Patients at High Risk of Recurrence?

FEATURING Martin Dietrich
  • 199 views
  • November 11, 2020
  • 1
11:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on mCRC: What Is the Antitumor Response With Pembro in the 1L MSI-H / dMMR Disease? Does the PFS Improve With Nivo? How Promising Is T-DXd in HER2+ Disease?

FEATURING Jason Starr
  • 58 views
  • September 16, 2020
15:39

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Stage 3 Rectal Cancer: Preoperative Short-Course RT, Followed by Chemo and TME vs. Conventional CRT - Which Option Leads to a Lower Rate of DrTF? Can Patients With a cCR to Neoadjuvant Skip Surgery?

FEATURING Jason Starr
  • 822 views
  • September 16, 2020
  • 5
20:20

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Pancreatic Cancer: mFOLFIRINOX vs. Gem/nab-P - Is There a Difference in Efficacy? Should We Consider Neoadjuvant FOLFIRINOX for Borderline Resectable Disease?

FEATURING Heloisa Soares
  • 1,641 views
  • September 16, 2020
  • 8
13:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Esophageal & HCC: CRT + Trastuzumab vs. CRT in Esophageal and GE Junction Adenocarcinomas, Trastuzumab/Pertuzumab to FLOT, Donafenib vs. Sorafenib in 1L Advanced HCC

FEATURING Heloisa Soares
  • 112 views
  • September 16, 2020